Corxel Pharmaceuticals has closed a USD 287 million Series D1 financing round, with proceeds earmarked primarily to advance its lead asset, CX11, an oral small molecule GLP-1R agonist. The candidate is currently in a Phase II trial for obesity and overweight in the US, while its partner, Vincentage, is conducting a Phase III trial for the same indication in their China homeland. The funds will also support other cardiovascular and metabolic programs, including assets for acute ischemic stroke and hypertension.

The company, originally incubated by RTW Investments, raised USD 162 million in its Series D round in 2024 with investments from Bayer and RTW. In December 2024, Corxel secured global rights (excluding Greater China) to CX11 from Vincentage. This latest capital injection is intended to accelerate CX11's global development, including planned Phase II trials for type 2 diabetes and preparatory work for Phase III studies.

According to PharmCube's NextBiopharm® database, Corxel's portfolio boasts four approved products. Click here to request a free trial for NextBiopharm®.